RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Contact
Reference Study ID Number: WO46069 https://forpatients.roche.com/
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive — TrialFind